Current Market Information

Last Trade Price (LTP) 62.00 Last Trade Date 15 October, 2026 Change 0.00 % Open Price 62.00 Day's Range 62.00 - 63.00     Total Trade 5 Total Volume 2600 Close Price 62.00 Yesterday Close Price 62.00 Market Capital in BDT (mn) 6659.805

Contact Information

Designation Name Mobile Number Email Chairman Mrs. Saiqa Mazed MD Professor Dr. Md. Jonaid Shafiq CFO Mr. Hassan Shahid Sarwar FCA Company Secretary Mr. Lorens Shamol Mollick FCS 01321131222 secretary@navanapharma.com Office Address 99 Gulshan Avenue,Rupayan Golden Age, 6th Floor, Plot-6, Block- CWN(C), Dhaka-1212 Phone : 02-55033580-3 Fax : 02-55033579 Email : cs@navanapharma.com Website : http://www.navanapharma.com Factory Address Rupshi, Rupganj, Narayanganj

Basic Information

Authorized Capital in BDT* (mn) 2,000.00 Paid-up Capital in BDT* (mn) 1,074.16 Face Value 10 Paid up Share 107416217     Market Lot 1 Sector PHARMA & CHEMICALS Market Category A

Other Information

Listing Year 2022 Debut Trade Date 18 October, 2022 Type of Instrument Equity     52 Week's Range 47.00 - 75.40 Year End 30 June Reserve / Surplus(mn) 3525.3 Remarks Tk. 1,671,330,888 Revaluation Reserve has been added to Reserve & Surplus. Note

Share Holding Percentage

Sponsor/Director Govt. Institute Foreign Public As on 30-Sep, 2026 31.64 0 11.11 19.63 37.62 As on 31-Aug, 2026 31.64 0 10.6 19.63 38.13 As on 31-Jul, 2026 31.64 0 11.02 19.63 37.71 As on 30-Jun, 2026 (year ended) 31.64 0 10.91 19.63 37.82     Remarks Note     Credit Rating Status Credit Rating Year Long Term Short Term Outlook Validity Date Credit Rating Company Dec 01, 2025 AA ST-2 Stable Nov 30, 2026 National Credit Rating Ltd. Dec 02, 2024 AA ST-2 Stable Dec 01, 2025 National Credit Rating Ltd. Aug 01, 2023 AA ST-2 Stable Jul 31, 2024 National Credit Rating Ltd.         Half Year End (HY) Information  202512 HY Net Turnover(mn)  5593.95 HY Net Profit after tax(mn)  362.67 HY EPS  3.35  AGM Information   AGM Date  31 December, 2025 Record Date  19 November, 2025 Dividend(%)  14.00 (Cash Dividend only for general shareholders-June 2025) Bonus Issue

   

Interim Financial Performance: 2026
Particulars	Unaudited / Audited
	Q1	Q2	Half Yearly	Q3	9 Months	Annual
	Ending on	Ending on	6 Months	Ending on		Ending on
	30-Sep-2025	31-Dec-2025	31-Dec-2025	31-Mar-2026		30-Jun-2026
Earnings Per Share (EPS)
Basic	1.690	1.670	3.380	1.220	4.590
Diluted*
Earnings Per Share (EPS) - continuing operations
Basic	1.690	1.670	3.380	1.220	4.590
Diluted*
Market price per share at period end

*As per BSEC Directive No. SEC/CMRRCD/2009-193/64, dated September 21, 2010.

*Note: For detail financial statements, please visit company’s website.

   

Financial Performance
Performance Year	Basic EPS Based On		Basic EPS (restated) Based On		Net Asset Value Per Share	Restated Net Asset Value Per Share	Net Profit After Tax(mn)		% Dividend	% Dividend Yield
	Continuous operations	Including Extra-Ordinary Income	Continuous operations	Including Extra-Ordinary Income			Continuous operations	Including Extra-Ordinary Income
2025	4.54	0	0	0	45.29	0	487.81	0	14%C	2.86
2024	3.77	0	0	0	42.46	0	404.63	0	14%C	1.59
2023	3.59	0	0	0	40.71	0	356.94	0	13%C	1.11
2022	3.42	0	0	0	43.41	0	274	0	11%C	0
2021	2.52	0	1.88	0	41.19	37.74	202.29	0		0

Financial Statements
Quarterly Financial Statement	https://navanapharma.com/page/quarterly-accounts
Price Sensitive Information	https://navanapharma.com/page/psi

Close Price and Traded Volume Graph
Click here to view 1 month graph	Click here to view 3 month graph	Click here to view 6 month graph
Form	To